Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

3 clinical studies listed.

Filters:

Lymphoma, Non-Hodgkin's, Adult

Tundra lists 3 Lymphoma, Non-Hodgkin's, Adult clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

RECRUITING

NCT06343311

T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

This is an open-label, multi-center, Phase 1/2 clinical trial evaluating the safety and effectiveness of EB103 in R/R B-cell NHL patients with the highest unmet medical needs, such as Human Immunodeficiency Virus (HIV)-associated lymphoma, primary and secondary central nervous system (CNS) lymphoma, and a wide range of high-grade B-cell lymphomas (HGBLs), as well as R/R large B-cell lymphoma (LBCL) patients ineligible for autologous transplant.

Gender: All

Ages: 18 Years - Any

Updated: 2026-10-01

5 states

B-Cell Non-Hodgkin's Lymphoma (NHL)
Lymphoma, Non-Hodgkins
Lymphomas Non-Hodgkin's B-Cell
+12
RECRUITING

NCT06510361

Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy

This research is being done to see if epcoritamab is effective in treating follicular lymphoma as a second line of treatment. The name of the study drug in this research study is: -Epcoritamab (a type of antibody)

Gender: All

Ages: 18 Years - Any

Updated: 2026-03-13

3 states

Lymphoma
Follicular Lymphoma
Lymphoma,Non-Hodgkin
+1
NOT YET RECRUITING

NCT05979857

Study of SP-3164 in Relapsed or Refractory Non-Hodgkin's Lymphoma

The purpose of this research is to help researchers find out if SP-3164 is safe and if it may be of benefit in the treatment of patients with Non-Hodgkin's lymphoma that has progressed after prior treatment, or that never responded to previous treatment.

Gender: All

Ages: 18 Years - Any

Updated: 2023-11-22

Lymphoma, Non-Hodgkin's, Adult